Management of Locoregional Recurrence in Breast Cancer

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

The 1-year progression-free survival rate for patients in the BCMA/GPRC5D naïve RP2D group was 95.0% and across all dose levels it was 74.1%.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD

May 26th 2025

THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Gina Mauro

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

THIO with cemiplimab is active and well-tolerated in patients with advanced non–small cell lung cancer resistant to immune checkpoint inhibitors in second- and third-line settings.

Rahul Banerjee, MD, FACP;Shernan Holtan, MD

March 3rd 2025

Olanzapine May Prevent Radiation-Induced Nausea and Vomiting

Shernan Holtan, MD, and Rahul Banerjee, MD, FACP, discussed various trials of significance shared as posters and presentations at the 2025 Tandem Meeting.

The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.

Roman Fabbricatore

ctDNA Analysis Shows Durvalumab/CRT Reduced Progression in Advanced Cervical Cancer

The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.

Ashley Chan

JNJ-79635322 Shows Safety/Favorable Responses in R/R Multiple Myeloma

The risk of progression was reduced with the use of durvalumab/CRT for advanced cervical cancer, according to an exploratory ctDNA analysis.

Related Content

Dylann Cohn-Emery

June 6th 2025

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

The 1-year progression-free survival rate for patients in the BCMA/GPRC5D naïve RP2D group was 95.0% and across all dose levels it was 74.1%.

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD

May 26th 2025

THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Gina Mauro

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

THIO with cemiplimab is active and well-tolerated in patients with advanced non–small cell lung cancer resistant to immune checkpoint inhibitors in second- and third-line settings.

Rahul Banerjee, MD, FACP;Shernan Holtan, MD

March 3rd 2025

Olanzapine May Prevent Radiation-Induced Nausea and Vomiting

Shernan Holtan, MD, and Rahul Banerjee, MD, FACP, discussed various trials of significance shared as posters and presentations at the 2025 Tandem Meeting.

Roman Fabbricatore

ctDNA Analysis Shows Durvalumab/CRT Reduced Progression in Advanced Cervical Cancer

The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.

Ashley Chan